California voters face a closely balanced November 2026 decision on Proposition 38, an initiated statute authorizing $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half allocated to a University of California-affiliated institute meeting specific criteria and the remainder distributed via competitive grants focused on cancer, heart disease, and Alzheimer’s. Trader consensus near 52% for passage reflects competing pressures: broad support for advancing medical research and potential revenue recapture through licensing offsets versus concerns over long-term General Fund repayment costs estimated at roughly $500 million annually, the measure’s structural emphasis on one qualifying nonprofit institute, and questions about fiscal accountability in a high-debt environment. Recent campaign activity, including endorsements and critiques highlighting eligibility requirements that favor established entities, has sustained the tight margin. Developments such as updated fiscal analyses, additional endorsements from research institutions, or shifts in statewide bond fatigue could alter the balance ahead of election day.